Mass. reaches $1.35M settlement with biotech company Stryker over product marketing

Mass. reaches $1.35M settlement with biotech co.

BOSTON — Massachusetts officials say a biotech company has agreed to pay $1.35 million to resolve allegations that it marketed medical products for purposes that had not been approved by regulators.

Attorney General Martha Coakley said in a statement Thursday that Hopkinton-based Stryker Biotech had compromised patient safety in pursuit of profits.

Authorities say Stryker promoted certain bone growth products for uses that had not been approved by the Food and Drug Administration. The attorney general alleges that Stryker then withheld information from health care professionals about the product’s use restrictions and falsified documentation.

Kalamazoo, Mich.-based parent company Stryker Corp. says the settlement is not an admission of liability.